-
Dong Huang,
Juying Qian,
Lei Ge,
Xuejuan Jin,
Huigen Jin,
Jianying Ma, Zongjun Liu,
Feng Zhang,
Lili Dong,
Xiangfei Wang,
Kang Yao,
Junbo Ge
[show abstract]
[hide abstract]
ABSTRACT: No randomized trial has been conducted to compare different vasodilators for treating no-reflow during primary percutaneous coronary intervention (PCI) for ST-segment elevation acute myocardial infarction.
The prospective, randomized, 2-center trial was designed to compare the effect of 3 different vasodilators on coronary no-reflow. A total of 102 patients with no-reflow in primary PCI were randomized to receive intracoronary infusion of diltiazem, verapamil, or nitroglycerin (n = 34 in each group) through selective microcatheter. The primary end point was coronary flow improvement in corrected thrombolysis in myocardial infarction frame count (CTFC) after administration of the drug.
Compared with that of the nitroglycerin group, there was a significant improvement of CTFC after drug infusion in the diltiazem and verapamil groups (42.4 frames vs 28.1 and 28.4 frames, P < .001). The improvement in CTFC was similar between the diltiazem and verapamil groups (P = .9). Compared with the nitroglycerin group, the diltiazem and verapamil groups had more complete ST-segment resolution at 3 hours after PCI, lower peak troponin T level, and lower N-terminal pro-B-type natriuretic peptide levels at 1 and 30 days after PCI. After drug infusion, the drop of heart rate and systolic blood pressure in the verapamil group was greater than that in the diltiazem and nitroglycerin groups.
Intracoronary infusion of diltiazem or verapamil can reverse no-reflow more effectively than nitroglycerin during primary PCI for acute myocardial infarction. The efficacy of diltiazem and verapamil is similar, and diltiazem seems safer.
American heart journal 09/2012; 164(3):394-401. · 4.65 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In the present study, a biomimetic phosphorylcholine group was employed in the end-capping modification of PEO-PPO-PEO tri-block co-polymers (Pluronic(®)). The structures of the resulting materials were characterized by (1)H-NMR and GPC. The effects of the additional phosphorylcholine end-groups to the thermo-sensitive sol-gel transition behaviors of the aqueous solutions of the resulting polymers were studied by rheology test in neutral (0.1 M NaCl) aqueous solutions and in acidic solutions (pH 3). It was found that the phosphorylcholine-end-capped Pluronic hydrogels still kept their thermo-sensitive mechanical properties with a slight change on the sol-gel transition behaviors. The phosphorylcholine-modified Pluronics exhibited a response to the change of the pH value, which made this kind of material a multi-sensitive hydrogel system. Also, the resulting polymers showed improved hemocompatibilities in the blood coagulation test using full human blood.
Journal of Biomaterials Science Polymer Edition 01/2011; 22(4-6):651-64. · 1.69 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: A biomacromolecular layer-by-layer coating process of chitosan/heparin onto a coronary stent is designed for the acceleration of the re-endothelialization and healing process after coronary stent deployment. The results of in vitro culturing of porcine iliac artery endothelial cells as well as the measurements of the APTT, PT and TT supported the rationale that the combination of chitosan and heparin could bring both endothelial cell compatibility and haemocompatibility to the stent surface. A porcine coronary injury model and arteriovenous shunt model were used for the further evaluation of the application of this kind of surface-modified stainless steel stent in vivo. The final results proved that this facile coating approach could significantly promote re-endothelialization and was safer compared with bare metal stents for its much improved anticoagulation property.
Biomaterials 02/2009; 30(12):2276-83. · 7.40 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In this study, the synthesis, characterization, and properties of a novel biodegradable polymer with improved hemocompatibility were introduced. It was synthesized by end-capping poly-ε-caprolactone (PCL) with phosphorylcholine (PC) groups. The polyester backbone provided the mechanical stability and biodegradability, while the PC-end groups improved its hemocompatibility. The obtained polymer was characterized using 1H NMR, 31P NMR, FTIR, and GPC, its crystallization behavior was studied by DSC. Compared with original PCL, the resulting polymer (PC-PCL) showed a lower crystallization capability and a faster degradation rate in PBS. The degradation rate of the polymer blends of PCL/PC-PCL increased with increasing PC-PCL content. The results of water contact angle measurements revealed a more hydrophilic surface property of PC-PCL than neat PCL. The hemocompatibility of PC-PCL was estimated using rabbit platelet-rich plasma, a better resistance to platelet adhesion and activation was observed. During the human blood plasma contacting process, PC-PCL showed a prolonged activated partial thromboplastin time over neat PCL. Material–cell interaction was evaluated with human umbilical vein endothelial cell, the result indicated that PC-PCL may to some extent have an antihyperplasia property, compared with neat PCL. © 2006 Wiley Periodicals, Inc. J Appl Polym Sci 103: 989–997, 2007
Journal of Applied Polymer Science 01/2007; 103(2):989 - 997. · 1.29 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In this paper, the synthesis, characterization, and properties of a novel biodegradable polymer with improved hemocompatibility is reported. It was synthesized by combining chitosan with phosphorylcholine (PC) groups through a heterogeneous reaction process. The structure of the obtained polymer was confirmed using solid state 13C NMR, 31P NMR, and elemental analysis. The phosphorylcholine modification increased water absorption while it decreases bovine serum albumin (BSA) adsorption of chitosan. Some biological properties of the resulting polymer (PC-chitosan) were tested and compared with native chitosan. The hemocompatibility of PC-chitosan was estimated using full human blood. Better resistance to coagulation was observed during the blood contacting process, with prolonged activated partial thromboplastin time (APTT). Material-cell interaction was evaluated using human umbilical vein endothelial cells (HUVECs). Good biocompatibility and cytophilicity of PC-chitosan was observed with less influence to cell differentiation and multiplication.
Carbohydrate Polymers.
